GENE ONLINE|News &
Opinion
Blog

2025-11-29|

Study Links DEHP and BPA to Molecular Pathways Associated with Polycystic Ovary Syndrome

by GOAI
Share To

A recent study has identified potential links between two widely used chemical compounds, Di(2-ethylhexyl) phthalate (DEHP) and Bisphenol A (BPA), and their role in Polycystic Ovary Syndrome (PCOS). Researchers, including Li, Jiang, and Zhu, conducted an in-depth analysis using advanced network toxicology and molecular docking techniques to explore the biological mechanisms through which these chemicals may influence the development or progression of PCOS.

The study examined how DEHP and BPA interact with molecular pathways associated with PCOS. By employing network toxicology, the researchers mapped out the complex interactions between these compounds and various biological targets. Molecular docking further allowed them to predict how these chemicals bind to specific proteins linked to PCOS-related processes. The findings provide detailed insights into the potential endocrine-disrupting effects of DEHP and BPA on reproductive health. The research highlights a need for further investigation into the implications of exposure to these chemicals in relation to PCOS.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 29, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top